BCRX
Price
$10.39
Change
+$0.32 (+3.18%)
Updated
May 22 closing price
Capitalization
2.17B
69 days until earnings call
EQ
Price
$0.39
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
14.14M
75 days until earnings call
Interact to see
Advertisement

BCRX vs EQ

Header iconBCRX vs EQ Comparison
Open Charts BCRX vs EQBanner chart's image
BioCryst Pharmaceuticals
Price$10.39
Change+$0.32 (+3.18%)
Volume$5.66M
Capitalization2.17B
Equillium
Price$0.39
Change-$0.00 (-0.00%)
Volume$173
Capitalization14.14M
BCRX vs EQ Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EQ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. EQ commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and EQ is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (BCRX: $10.39 vs. EQ: $0.39)
Brand notoriety: BCRX: Notable vs. EQ: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 117% vs. EQ: 0%
Market capitalization -- BCRX: $2.17B vs. EQ: $14.14M
BCRX [@Biotechnology] is valued at $2.17B. EQ’s [@Biotechnology] market capitalization is $14.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileEQ’s FA Score has 1 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • EQ’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than EQ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while EQ’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 5 bearish.
  • EQ’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, EQ is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а +1.76% price change this week, while EQ (@Biotechnology) price change was -1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.00%. For the same industry, the average monthly price growth was +5.57%, and the average quarterly price growth was -1.69%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

EQ is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($2.17B) has a higher market cap than EQ($14.1M). BCRX YTD gains are higher at: 38.165 vs. EQ (-48.530). BCRX has higher annual earnings (EBITDA): 47.6M vs. EQ (-4.46M). BCRX has more cash in the bank: 295M vs. EQ (25.9M). EQ has less debt than BCRX: EQ (497K) vs BCRX (795M). BCRX has higher revenues than EQ: BCRX (503M) vs EQ (45.9M).
BCRXEQBCRX / EQ
Capitalization2.17B14.1M15,418%
EBITDA47.6M-4.46M-1,066%
Gain YTD38.165-48.530-79%
P/E RatioN/AN/A-
Revenue503M45.9M1,096%
Total Cash295M25.9M1,139%
Total Debt795M497K159,960%
FUNDAMENTALS RATINGS
BCRX vs EQ: Fundamental Ratings
BCRX
EQ
OUTLOOK RATING
1..100
6855
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
23
Undervalued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
3894
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EQ's Valuation (23) in the Biotechnology industry is in the same range as BCRX (32). This means that EQ’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for EQ (100). This means that BCRX’s stock grew somewhat faster than EQ’s over the last 12 months.

EQ's SMR Rating (92) in the Biotechnology industry is in the same range as BCRX (100). This means that EQ’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for EQ (94). This means that BCRX’s stock grew somewhat faster than EQ’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EQ (100). This means that BCRX’s stock grew similarly to EQ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXEQ
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EQ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHXIX13.650.05
+0.37%
American Beacon Shapiro Equity Opps R5
TRSAX98.61N/A
N/A
T. Rowe Price Growth Stock Adv
DPRIX67.44N/A
N/A
BNY Mellon Worldwide Growth Y
RPTTX47.45N/A
N/A
T. Rowe Price Diversified Mid Cap Gr I
SMDLX21.87N/A
N/A
ClearBridge Tactical Dividend Income C

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+3.18%
VCYT - BCRX
46%
Loosely correlated
N/A
CRNX - BCRX
40%
Loosely correlated
+0.53%
ABEO - BCRX
39%
Loosely correlated
N/A
BEAM - BCRX
38%
Loosely correlated
N/A
DNLI - BCRX
37%
Loosely correlated
-0.22%
More

EQ and

Correlation & Price change

A.I.dvisor indicates that over the last year, EQ has been loosely correlated with MTNB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EQ jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EQ
1D Price
Change %
EQ100%
N/A
MTNB - EQ
38%
Loosely correlated
N/A
IMNM - EQ
33%
Poorly correlated
+6.82%
PRQR - EQ
28%
Poorly correlated
-1.74%
WVE - EQ
26%
Poorly correlated
N/A
MURA - EQ
24%
Poorly correlated
N/A
More